Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Receivables: 2010-2025

Historic Change in Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $57.0 million.

  • Arrowhead Pharmaceuticals' Change in Receivables was N/A to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.0 million, marking a year-over-year change of. This contributed to the annual value of $57.0 million for FY2025, which is N/A change from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Change in Receivables stood at $57.0 million for FY2025, which was up 4,140.21% from -$1.4 million recorded in FY2023.
  • In the past 5 years, Arrowhead Pharmaceuticals' Change in Receivables registered a high of $57.0 million during FY2025, and its lowest value of -$8.8 million during FY2022.
  • For the 2-year period, Arrowhead Pharmaceuticals' Change in Receivables averaged around $27.8 million, with its median value being $27.8 million (2023).
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Change in Receivables soared by 5,013.59% in 2021, and later tumbled by 194.01% in 2022.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Change in Receivables (Yearly) stood at $9.4 million in 2021, then tumbled by 194.01% to -$8.8 million in 2022, then skyrocketed by 84.06% to -$1.4 million in 2023, then reached $57.0 million in 2025.